BLC2001: Phase II Trial of FGFR Inhibitor Erdafitinib in Patients With FGFR-Altered Metastatic or Unresectable Urothelial Carcinoma

June 1-5, 2018; Chicago, Illinois
This trial met its primary endpoint with an ORR of 40% and showed a manageable and well-tolerated safety profile for erdafitinib in FGFR-altered UC.
Format: Microsoft PowerPoint (.ppt)
File Size: 190 KB
Released: June 12, 2018


Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Celgene Corporation
Janssen Therapeutics
Merck & Co., Inc.
Seattle Genetics

Related Content

Clinical Care Options (CCO): Dr Heather Cheng answers audience questions from a live symposium on current and expanding role of PARP inhibitors in prostate cancer care

Heather H. Cheng, MD, PhD Released: April 26, 2022

Clinical Care Options (CCO): Expert analysis from Drs. Daniel Petrylak and Toni Choueiri on key data in genitourinary cancers from ASCO GU 2022

Toni K. Choueiri, MD Daniel P. Petrylak, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: April 18, 2022 Expired: April 17, 2023

Clinical Care Options (CCO): Atish Choudhury, MD, PhD, provides insights into new and evolving treatment approaches in CSPC, including data from 2022 ASCO GU Cancers Symposium

Atish Choudhury, MD, PhD Released: March 30, 2022

On-demand Clinical Care Options (CCO) webcast: experts discuss treatment of castration-sensitive prostate cancer, including data from 2022 ASCO GU Cancers Symposium

Atish Choudhury, MD, PhD Michael S. Cookson, MD, MMHC, FACS David F. Jarrard, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: March 14, 2022 Expired: March 13, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings